-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 9, Kelun's 4-type generic application for linagliptin tablets was approved, becoming the fourth domestic company
Figure 1: Kelun's latest approved products
Source: NMPA official website
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy or in combination with metformin hydrochloride or with metformin hydrochloride and The combination of sulfonylureas is used to improve glycemic control in patients with type 2 diabetes who cannot effectively control blood sugar with these drugs alone or in combination
Data shows that Guangdong Sunshine Pharmaceutical won the first domestic imitation of linagliptin tablets as early as 2020.
Figure 2: 2021E China Urban Physical Pharmacy Terminal Non-insulin Hypoglycemic Drugs Oral TOP20 Variety Pattern
Source: Minet.
According to the data of Minet.
Figure 3: Sales of linagliptin by Boehringer Ingelheim (unit: ten thousand yuan)
Source: Minet.
In recent years, Boehringer Ingelheim's linagliptin has maintained a positive growth trend in physical pharmacy terminals in Chinese cities.
Earlier, Kelun has obtained the production approval for glipizide capsules, empagliflozin tablets, canagliflozin tablets and sitagliptin phosphate tablets.